Esophageal cancer drug combo trial pulled before starting
NCT ID NCT05312372
First seen Feb 20, 2026 · Last updated Apr 28, 2026 · Updated 9 times
Summary
This study was designed to test a new drug (S095033) combined with a standard chemotherapy (paclitaxel) in people with advanced or metastatic esophageal squamous cell carcinoma. The goal was to see if the combination was safe and could shrink tumors. However, the trial was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.